tirzepatide approved for obesity F.D.A. Approves New Drug That Will Compete With Wegovy Tirzepatide for the Maintenance of

Visit Clinic Meet with our medical team for a thorough consultation and personalized treatment plan

GLP-1

Clinical trials and prospective studies will be essential

Robustness was evaluated with deterministic and probabilistic sensitivity analyses

Among patients with polycystic ovary syndrome (PCOS), the median one-year weight change was an 11.5% loss for those treated with a GLP-1, compared to a 1.9% loss among those treated with metformin.

This systematic review evaluates the literature on the relationship between GLP-1 RA use and increased regurgitation and aspiration events to contextualize the existing, consensus-based guidelines put forth by the ASA in light of limited comparative evidence